Explore

Bipartisan Lawmakers Reintroduce Bill to Address High Heart Disease Risk in South Asian Americans

Bipartisan Lawmakers Reintroduce Bill to Address High Heart Disease Risk in South Asian Americans

A bipartisan group of U.S. lawmakers has reintroduced the South Asian Heart Health Awareness and Research Act. This legislation aims to increase federal research, public awareness, and culturally appropriate programs to address the disproportionately high incidence of heart disease among South Asian Americans. Representatives Pramila Jayapal and Joe Wilson, along with Senator Cory Booker, introduced the bill. The measure would authorize the U.S. health secretary to provide grants to states for programs focusing on communities severely affected by cardiovascular disease. The bill also seeks to ensure that research funding is directed towards risk factors that have not received adequate attention. South Asians in the United States face four times the risk of heart disease compared to the general population, with nearly two-thirds of middle-aged South Asian Americans facing an intermediate or high risk of heart failure within the next decade. The legislation is co-sponsored by Representatives Nanette Barragan...

Exploratory Study Identifies Ferroptosis-Related Transcriptional Patterns in Dilated Cardiomyopathy and Cancer Datasets

Exploratory Study Identifies Ferroptosis-Related Transcriptional Patterns in Dilated Cardiomyopathy and Cancer Datasets

An exploratory study has investigated ferroptosis-related transcriptional patterns in dilated cardiomyopathy (DCM) and pan-cancer datasets. The research, which utilized single-cell data from one DCM donor and one non-diseased donor, along with a mixed-heart-failure bulk cohort and pan-cancer expression summaries, aimed to understand the relevance of ferroptosis pathways in these conditions. The study found that among 109 detected ferroptosis-related genes, 60 met an 'up' threshold and 24 met a 'down' threshold in cell-level Wilcoxon analysis. Notably, cardiomyocytes, macrophages, and endothelial cells were not detected in the selected DCM donor, limiting condition-specific comparisons for these cell types. The composite ferroptosis score was higher in DCM cells compared to normal cells, though this observation is confounded by donor and composition differences. Cross-platform correlation of fold changes for ferroptosis-related genes between single-cell and bulk datasets was absent, and RT-qPCR assessments ...

The Role of the Citric Acid Cycle Explained

The Role of the Citric Acid Cycle Explained

The citric acid cycle, often referred to as the Krebs cycle, stands as a cornerstone of metabolism in all aerobic organisms. This intricate biochem...

Discontinuing Ozempic Increases Risk of Heart Attack and Stroke, Study Finds

Discontinuing Ozempic Increases Risk of Heart Attack and Stroke, Study Finds

A new study by Washington University in St. Louis indicates that discontinuing GLP-1 medications, such as Ozempic, significantly elevates the risk of cardiovascular disease. Patients who stopped taking these medications experienced a 22% higher likelihood of heart attack, stroke, or death within two years compared to those who continued treatment. The study, published in the scientific journal BMJ Medicine, involved over 333,000 U.S. veterans with type 2 diabetes. It revealed that the positive cardiovascular effects of Ozempic rapidly diminish after treatment cessation. Even a six-month interruption in treatment was found to significantly reduce the medication's protective effect. Researchers noted that many patients discontinue these drugs due to high cost, side effects, or shortages. Upon cessation, not only does lost weight return, but inflammatory processes, blood pressure, and cholesterol levels also increase, leading to a 'metabolic shock' that negatively impacts heart health.

Representative Kim Schrier Appointed Co-chair of Congressional Diabetes Caucus

Representative Kim Schrier Appointed Co-chair of Congressional Diabetes Caucus

Representative Kim Schrier (D-WA) has been named the new Co-chair of the Congressional Diabetes Caucus, taking over from Congresswoman Diana DeGette (D-CO), who held the position since 1999. This announcement was made on September 21, 2026. Breakthrough T1D Chief Global Advocacy Officer Lynn Starr expressed gratitude for Congresswoman DeGette's extensive contributions, which included securing over $2.5 billion for T1D research through the Special Diabetes Program, advancing stem cell research, and accelerating innovative T1D therapies via the 21st Century Cures Act. Representative Schrier, a pediatrician and the only current member of Congress living with Type 1 diabetes, is seen as a highly suitable successor. Her personal and professional background is expected to provide valuable insight and leadership to the caucus, ensuring continued advocacy for the diabetes community.

University of Waterloo Researchers Investigate Green Tea Extract for Alzheimer's Prevention

University of Waterloo Researchers Investigate Green Tea Extract for Alzheimer's Prevention

Researchers at the University of Waterloo are investigating the potential of epigallocatechin gallate (EGCG), a plant antioxidant found in green tea, as a preventative treatment for Alzheimer's disease. Three students in Dr. Zoya Leonenko's lab are studying how EGCG might protect against cell damage linked to the neurodegenerative disease. Their work focuses on the neuronal membrane and its response to amyloid beta, a protein cluster that forms plaques in the brain and is a major contributor to Alzheimer's. Using electrophysiology techniques, researchers Charlotte Baur and Hugh Hossfeld are examining how amyloid beta damages the membrane and if EGCG can offer protection by reducing ion permeability. Isabella Barichello is using surface plasmon resonance (SPR) to study how amyloid beta attaches to the membrane's surface and whether EGCG can reduce or prevent this buildup.

Researchers Identify Brain Immune Modulation as Potential Alzheimer's Treatment Strategy

Researchers Identify Brain Immune Modulation as Potential Alzheimer's Treatment Strategy

Professor Minah Suh of Sungkyunkwan University, in collaboration with biotechnology company IMNEWRUN and Professor Ho-Keun Kwon's team at Yonsei University College of Medicine, has identified a new mechanism for treating Alzheimer's disease. Their research, published in the journal Science Advances, demonstrates that modulating an immune protein in the brain can restore a disrupted brain immune environment and reduce abnormally elevated neuronal activity in an animal model of Alzheimer's. Alzheimer's disease is characterized by harmful protein deposits and dysfunction of cells, particularly microglia, which are the brain's resident immune cells. In Alzheimer's, microglial responsiveness is impaired, and neurons exhibit increased activity. The research team focused on immune-regulatory proteins PD-1 and PD-L1, finding increased expression of PD-1 in microglia and PD-L1 in astrocytes in Alzheimer's model mice. By administering an antibody that blocks PD-L1 activity directly into the brains of these mice, the...

European Association of Urology to Host Joint Meeting in Ghent Addressing Gaps in Genitourinary and Andrology Knowledge

European Association of Urology to Host Joint Meeting in Ghent Addressing Gaps in Genitourinary and Andrology Knowledge

The European Association of Urology (EAU) is organizing a joint meeting in Ghent, Belgium, scheduled for September 24-25, 2026. This event will bring together the EAU Section of Genito-Urinary Reconstructive Surgeons (ESGURS) and the EAU Section of Andrological Urology (ESAU). The meeting aims to address existing knowledge gaps and clinical practice challenges within genitourinary reconstructive surgery and andrology. Despite the availability of EAU guidelines in these fields, the organizers recognize that several unmet needs persist. The program will feature a combination of live surgery demonstrations and plenary sessions, providing a comprehensive platform for discussion and learning. A new addition to this year's event is a networking session designed to foster greater interaction between faculty members and participants, promoting collaboration and knowledge exchange among leading experts in the field.

Mandelic Acid's Role in Organic Synthesis Studied

Mandelic Acid's Role in Organic Synthesis Studied

Mandelic acid, an aromatic alpha hydroxy acid, is a compound of considerable importance in the chemical and pharmaceutical industries. Known for it...

What Makes Citric Acid Nature's Versatile Compound

What Makes Citric Acid Nature's Versatile Compound

Citric acid is a fascinating organic compound, recognized for its colorless nature and its classification as a weak organic acid. Its chemical form...

Advocates Call for Bipartisan Action on Menopause Research and Care on Capitol Hill

Advocates Call for Bipartisan Action on Menopause Research and Care on Capitol Hill

The Women’s Health Advocates (WHA), the National Menopause Foundation, and Perry are hosting the first-ever Perimenopause and Menopause Capitol Hill Day on September 22. This event brings together over 125 advocates from 29 states to Washington D.C. to push for bipartisan action on critical issues related to menopause. The primary goals include increasing research investment, improving clinician education, expanding access to care, ensuring adequate coverage, and developing supportive workplace policies for menopause. Liz Powell, Esq., MPH, Founder of Women’s Health Advocates, highlighted that despite impacting 71 million women in the U.S., there is currently no legislation addressing gaps in menopause research, education, and care. The event will also feature a congressional briefing with experts from various organizations, following a recent bipartisan congressional hearing on menopause hosted by the Senate Special Committee on Aging, which requested the Government Accountability Office to assess federal...

FDA Moves to Reduce Animal Testing Requirements for Drug Approval

FDA Moves to Reduce Animal Testing Requirements for Drug Approval

The U.S. Food and Drug Administration (FDA) has issued a direct final rule aimed at removing outdated references to animal testing in its drug and biologics regulations. This action is a significant step towards encouraging drug companies to utilize cutting-edge non-animal testing methods. Despite the FDA's public commitment to advancing non-animal test methods, existing regulations have often led companies to believe that animal testing is a mandatory requirement for drug approval. The new rule, which could become effective as early as February 4, 2027, directly responds to a 2024 legal petition filed by Humane World for Animals and Humane World Action Fund. These organizations advocated for the FDA to clarify that animal testing is not legally required. This initiative aligns with the FDA's stated goal of making animal tests "the exception rather than the norm" for preclinical safety and toxicity testing within the next three to five years.